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Abstract 
Objective: To determine the impact of pharmacist conducted Comprehensive Medication Review (CMR) follow-up within seven days 
after discharge on (1) readmission rates, (2) detection of drug related problems, (3) and changes in Hospital Consumer Assessment of 
Healthcare Providers and Systems (HCAHPS) scores.  Design: Rates of re-admission for pneumonia, congestive heart failure (CHF), or 
myocardial infarction (MI), within 30 days of discharge are compared between patients receiving a CMR from the pharmacist to a 
historical control group not receiving the service.  The CMR documentation is reviewed to classify any detected drug related 
problems.  Overall HCAHPS scores for the hospital are compared for the three months prior to instituting this service and the three 
months during the service.  Setting: Patients were discharged from a 101-bed acute care hospital located in rural West Virginia.  The 
community pharmacist worked with the hospital to contact patients after discharge to demonstrate a partnership between inpatient 
and outpatient care. Patients: Patients were included if they had a discharge diagnosis of pneumonia, congestive heart failure (CHF), 
or myocardial infarction (MI), and were returning to self-care or family-care.  If discharged between 10/12/2012 and 12/11/2012 
they were included in the historical control group.  If discharged between 12/12/2012 and 2/12/2012 they were offered the CMR 
service and included in the intervention group. Intervention: Patients received a telephone call two to seven days following discharge 
from a pharmacist who conducted the Comprehensive Medication Review (CMR). Results: Patients who participated in a CMR via the 
telephone had decreased 30-day readmission rates compared to the historical control group (16% v 33%).  Overall 22 significant drug 
therapy problems were identified among patients.  HCAHPS scores for the questions “Did you receive communication regarding your 
medications” increased during the study time period (65% vs 72%).  Conclusion: The mixed results of available data from previous 
studies on pharmacist inclusion in the discharge process focuses heavily on counseling before the patient is discharged.  Results of 
this study show community pharmacist partnership in discharge follow-up can also assist in decreasing readmissions, detecting drug 
related problems, and increasing patient satisfaction. 
 
 
Introduction 
According to the Centers for Medicare and Medicaid Services 
(CMS), approximately 20% of Medicare patients are 
readmitted within 30 days. (1) Patients admitted to a hospital 
due to pneumonia, myocardial infarction, or congestive heart 
failure have been identified by CMS as high risk populations 
for readmission.  In an effort to improve overall health 
management for these high-risk groups, CMS has announced 
decreases in reimbursement rates for hospitals in the event 
that a patient is re-admitted for the same diagnosis within 30 
days of discharge.  CMS now also promotes prompt follow-up 
visits after a patient is discharged, by increasing the 
reimbursement rate for an outpatient evaluation and  
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management visit if its (a) coupled with verbal patient 
contact within 48 hours of discharge, and (b) the provider 
visit is held within 7 to 14 days of discharge.   
It has been found that 20% of patients experience an adverse 
event (ADE) following discharge, with 66% of those being 
medication related (2).  Among these, six medication classes 
were implicated as causative agents of the ADEs in 87% of 
cases.  These included anti-infectives, corticosteroids, 
cardiovascular medications, analgesics, anticoagulants and 
antiepileptics.   The most common reasons for ADEs included 
the lack of appropriate drug monitoring and the lack of 
evaluation of predictable medication side effects. (3)  
Recently, there has been great attention on methods to 
reduce readmissions, decrease adverse drug events, and 
increase patient understanding of their medications upon 
discharge.  Programs like Project RED (Re-engineered 
Discharge) (4) the Care Transitions Program (5) and Project 
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BOOST (Better outcomes for older adults through safe 
transitions) (6) have all demonstrated methods that are 
successful in reducing readmissions. 
These three projects target reducing readmissions by focusing 
on steps in a patient’s transition from one setting of care to 
another, known as “transitions of care” (TOC).  One of the 
frequently studied areas includes patients discharged from 
hospital to home.  Pharmacist involvement in the transitions 
from hospital to home has been shown to be beneficial at 
various points during the discharge process. (7) According to 
the PILL-CVD study, pharmacist medication reconciliation and 
discharge counseling was shown not to be beneficial in 
reducing clinically important medication errors in the 30 days 
following discharge.  It is important to note while this study 
focused on patients with heart failure and acute coronary 
syndromes, they were of a low health literacy level. (8) In 
contrast, Schnipper, et al. found that providing pharmacist 
discharge counseling and follow-up 3 to 5 days post-discharge 
was associated with a decreased rate of preventable ADEs 
following discharge. (9) 
Previous literature regarding pharmacist involvement has 
focused on discharge counseling on medications provided by 
the pharmacist at the bedside. (7) A recent systematic review 
of medication reconciliation identified pharmacists as key 
players in discharge processes. (10) Overall, the most 
frequently studied post-discharge interventions are follow-up 
calls with patients.  All of these included medication 
reconciliation.   
Three studies have measured post-discharge follow-up calls 
with medication reconciliation and a review of follow-up 
instructions provided by different members of the healthcare 
team. (7) Two studies found no effect on the rate of 30-day 
readmission, while one showed an effect with follow-up calls 
completed by pharmacists on detection of preventable 
adverse drug events (ADEs) and decreased visits to the 
Emergency Department. (11) This mixed result from the 
performance of medication reconciliation introduces a 
question of the utility of an accurate medication list versus 
the same list compounded by pharmacist counseling.   
A closer look at the definitions of medication reconciliation 
and CMR help identify the difference that may be introduced 
by having a pharmacist perform medication reconciliation 
and discharge follow-up. According to CMS, medication 
reconciliation is defined as the process of identifying the most 
accurate list of all medications that the patient is taking, 
including name, dosage, frequency, and route, by comparing 
the medical record to an external list of medications obtained 
from a patient, hospital, or other provider. (12) The National 
Medication Therapy Management Advisory Board defines a 
CMR as: a systematic process of collecting patient-specific 
information, assessing medication therapies to identify 
medication-related problems, developing a prioritized list of 
medication-related problems, and creating a plan to resolve 
them with the patient, caregiver and/or prescriber. (13) 
Inherent in this definition is that a CMR includes medication 
reconciliation, but is augmented by the professional expertise 
of a pharmacist.   
A CMR is an interactive person-to-person consultation 
conducted between the patient and/or caregiver and the 
pharmacist designed to improve patients’ knowledge of their 
prescription, over-the-counter (OTC) medications, herbal 
therapies and dietary supplements, identify and address 
problems or concerns that patients may have, and empower 
patients to self-manage their medications and their health 
condition(s). (13) CMRs are frequently conducted by 
community pharmacists, but most of the literature focuses on 
interventions that align with the definition of medication 
reconciliation rather than a CMR. (12)  
Currently, there are few studies highlighting the use of a 
community pharmacist in this realm.  For example, Walgreens 
is promoting their WellTransitions® program which 
incorporates bedside delivery of medications, follow-up with 
the patient at 9 and 25 days post-discharge by a pharmacist, 
and connections with their primary care providers. (14) Based 
on the minimal amount of evidence of community pharmacist 
involvement in the discharge follow-up process, the objective 
of this study was to determine the impact of a pharmacist 
conducted CMR via telephone within 7 days post-discharge 
on readmission rates, detection of drug related problems, 
and patient satisfaction scores through HCAHPS. 
 
Methods 
This pilot was approved by the University of Charleston 
Institutional Review Board and representatives of the study 
hospital and conducted from December 12, 2012 through 
March 12, 2013 at the study hospital.  Patients were 
identified by a nurse case manager and invited to participate 
in the study if they had a diagnosis of congestive heart failure 
(CHF), pneumonia, or myocardial infarction (MI) and gave 
informed consent.  Those included must also be 18 years or 
older, have access to a telephone, and speak 
English.  Patients were identified and contacted during the 
first three months of the study (December 12, 2012 through 
February 12, 2013), while the remaining month was left for 
30-day follow-up on readmission status with those patients 
called within the final month (March 2013). 
The pharmacist with training and experience in performing a 
CMR reviewed discharge medication records and instructions 
prior to calling patients.  Participating patients were 
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contacted between two and seven days post-discharge.  The 
pharmacist attempted to call patients three times before 
excluding them from the study.   
The pharmacist used a standardized CMR questionnaire form 
to document the encounter. (Appendix A) The CMR included 
indication for therapy, dosing/duration, side effects, 
adherence or access to medications, drug/drug interactions, 
and drug/food interactions for each medication, self-
monitoring for the admitting/discharge diagnosis, self-
monitoring for medication side effects, immunization record 
evaluation, and specific questions related to disease states of 
CHF and COPD.  Questions related to COPD were included 
because the diagnosis of pneumonia leads to a high-incidence 
of re-admission among COPD patients.   All patients were 
asked about any difficulty filling prescriptions following 
discharge.  Drug therapy problems and discrepancies were 
documented using the Coleman Medication Discrepancy 
Tool
©
 (MDT) for community dwelling adults. (5) After the call, 
a second clinical pharmacist was consulted to confirm 
evaluation and documentation of drug related 
problems.  Patients were then mailed a reconciled list of their 
medications with self-monitoring guidance.  At least 30 days 
following discharge, the patient’s EHR was reviewed for any 
readmissions.  Patients were  called at this point to review 
readmission status to other facilities such as the ER, urgent 
care, or unscheduled physician visits. 
The historical control group consisted of patients discharged 
with one of the target diagnoses in the three months prior to 
the study period during the dates October 12, 2012 through 
December 11, 2012.  These patients received the standard 
discharge medication counseling from nursing staff and did 
not receive a telephone follow-up call at the 30 day mark to 
determine readmission status.  The pharmacist reviewed 
patient records to detect any readmissions within 30 days of 
discharge 
Results 
During the three month study period, 25 patients met the 
inclusion criteria (Figure 1).  Of these, 7 were lost due to 
inability to contact within the designated time frame (Figure 
1).  A total of 18 patients received the CMR service.  In the 
intervention group there were three (16%) patients 
readmitted within 30 days of discharge, however only two of 
these readmissions were related to the initial diagnosis (11%), 
while one (5%) was not. (Table 2) These re-admissions were 
to the study hospital and were detected by the record review 
process.  
The historical control group consisted of 24 community 
dwelling patients discharged with one of the diagnoses listed 
(Table 1).  Of these, eight (33%) were readmitted to the study 
hospital with the same diagnosis (Table 2).  Since these 
patients received no 30-day follow-up call for readmission 
status, there is potential for higher readmission rates for the 
control group to other facilities, which would be unaccounted 
for in our study. 
Hospital Consumer Assessment of Health Care Providers and 
Services (HCAHPS) scores were compared for the control and 
intervention groups.  HCAHPS is a survey sent to all patients 
following their hospital stay.  One of the main focuses of 
HCAHPS is on the importance of communication about 
medications.  When those in the control group were asked if 
they received communication about their medications, 65% 
answered yes.  During the three month study period, 72% of 
patients answered yes to this question, showing an 
improvement in patient satisfaction for this domain.  These 
results for HCAHPS scores included all patients surveyed by 
the hospital, and not just those included in the study. 
There were 22 significant drug therapy problems detected in 
the intervention group.  Several patients experienced more 
than 1 drug therapy problem (Table 3).  The most common 
problems identified were needs additional therapy (9), 
adverse drug reactions (3), and patient non-adherence 
(3).  Often when patients were called, it was found they had 
not picked up their new discharge medications from the 
pharmacy or were non-adherent with other medications at 
home.  This may have potentially led to their admission or a 
future re-admission.  Not all drug therapy problems were 
related to a patient’s admitting diagnosis; however, any 
problem may have led to additional physician visits or 
hospital admissions in the future.  This demonstrates the 
importance of reviewing all medications with a patient 
following discharge, and not only their new or altered 
regimen. 
 
Discussion 
Pharmacist involvement in transitions of care elements has 
been continually shown to be beneficial at various points in 
the healthcare spectrum a patient may access.  A recent 
systematic review of medication reconciliation identified 
pharmacists as key players in discharge process. (10) Previous 
literature focused on pharmacist involvement at pre-
discharge counseling (7).  The most frequently studied post-
discharge interventions are follow-up calls, but these were 
rarely studied in isolation. 
As a community pharmacist serving as a liaison between the 
inpatient and outpatient setting, there were barriers to 
initially be recognized as a contributor to preventing 
readmissions within the acute care setting.  When presenting 
the concept of this project to hospital administration and 
staff, a lot of initial groundwork had to be done.  Most 
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hospital employees were unfamiliar with the concept of a 
CMR and that CMRs are provided at their local 
pharmacy.  Inpatient medications change too rapidly to 
conduct a CMR versus traditional medication reconciliation in 
the institutional setting.  CMRs target self-care patients with a 
variety of disease states, which puts community pharmacists 
in an ideal position to provide these important services. 
In this study, the institution granted the pharmacist access to 
the electronic health record (EHR).  However, the lack of 
access to this critical information is often a significant barrier 
to communication in the community pharmacy setting.  The 
lack of access for hospitals, physicians, and pharmacies to 
patient health information could be easily remedied by the 
implementation of a universal EHR.  There is very little 
literature discussing the role of community pharmacists 
participating in these interventions.  This pilot study 
demonstrates that a community pharmacist can serve as a 
connection for patients in the outpatient setting in 
conjunction with their physician(s) and hospital.  It offers 
patients another piece to a support system in medication 
management at home.  Future research may include having 
follow-up visits with patients in a community pharmacy 
setting to review medication issues prior to a follow-up visit 
with their physician to determine the impact of face to face 
contact versus telephone contact. 
Through the phone call, the pharmacist was able to answer 
questions the patient had regarding their medications, refer 
patients to their physician when appropriate, and even assist 
patients with getting their new medications through 
pharmacy delivery services. Not all drug therapy problems 
were related to a patient’s admitting diagnosis, but any 
problem may have led to additional physician visits or 
hospital admissions in the future.  This demonstrates the 
importance of reviewing all medications with a patient 
following discharge, and not only their new or altered 
regimen.  
The decreased number of readmissions in the intervention 
group may have been related to the detection of drug related 
problems, reinforcement of self-monitoring principles, 
counseling received on previous home medications, or the 
positive impact of the contact. 
Limitations 
The small sample size of this pilot study does not provide 
enough power to report statistically significant 
conclusions.  In the future, including patients with additional 
diagnoses targeted by CMS for readmission reduction, or 
extending the time frame for data collection may result in a 
larger sample size.  The sample size was also limited by the 
difficulty contacting patients via phone within the time frame 
required.  This might have been improved if patients had 
been given a specific appointment time for the phone CMR 
session, or if multiple pharmacists were offering the service 
at various times.  Completing a CMR is a time consuming 
process and requires additional staffing resources to continue 
as a mainstay of pharmacist involvement in discharge 
interventions.  One addition to improve the efficiency of the 
pharmacist would be using pharmacy technicians to arrange 
the phone appointments, and secure commitment from the 
patient for the appointment time. 
A variety of communication challenges existed during the 
study.  Patients could not always be contacted at home 
during the study time frame of two to seven days post-
discharge.  When using one pharmacist with multiple other 
responsibilities to make all follow-up calls, this presents a 
challenge.  No analysis was conducted to determine the best 
time frame for contacting patients.   
Readmissions were categorized based on admitting 
diagnosis.  While this is appropriate to measure the ultimate 
financial impact on the hospital secondary to financial 
penalties imposed by CMS for readmissions, this method did 
not discern whether readmissions were medication related, 
due to another disease, or medication injury. 
Finally, although a standard CMR form was used for all 
patients, due to variability in their medications and disease 
states, the call could have proceeded in various directions.  If 
multiple pharmacists were conducting this service in the 
future, a more standardized script for each disease state 
would need to be implemented. 
Conclusion 
The burden for patients following discharge and reducing 
readmissions is a key area of practice and current research, 
especially concerning the financial penalties associated with 
readmissions.  This pilot study demonstrates that pharmacist 
involvement in discharge follow-up can be important to 
reducing readmissions and detecting drug related problems 
at the study hospital.   This reinforces the value of using a 
medication specialist to improve the quality of transitions of 
care.  To conduct successful research in the future and to 
increase the volume of patients contacted, institutions should 
use more than one pharmacist to provide such services.  This 
would allow for a greater number of patients to be reached in 
a specific time frame.  Enlisting the help of technician staff, or 
finding a more efficient way of scheduling appointments 
would lessen the burden of the process, allowing the 
pharmacist to more correctly focus their time on the patient.  
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Figure 1: Patient Inclusion and Exclusion 
 
Total Patients Discharged from Hospital with an index 
diagnosis of PNA, MI, or CHF 
N=42 
 
Eligible patients lost to exclusion criteria/no informed 
consent 
N=17 
 
Patients unable to reach in 7 days 
N=7 
 
 
Patients contacted with CMR 
N=18 
 
 
 
 
Table 1: Characteristics and Diagnoses of Population 
Characteristic Intervention Group Control Group 
N 18 24 
Age range 49-82 45-92 
Diagnosis of CHF 11 17 
Diagnosis of PNA 8 5 
Diagnosis of MI 1 2 
>1 Inclusion Diagnosis 4 3 
 
CHF=Congestive Heart Failure, PNA=Pneumonia, MI=Myocardial Infarction 
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Table 2: 30-day Readmission Rates 
 
 
Intervention Group Historic Control Group 
N 18 24 
Index diagnosis at discharge (some patients had more than 1 diagnosis) 
  PNA 
  MI 
  CHF 
 
8 
1 
11 
 
12 
2 
10 
30-day readmissions 3 (16%) 8 (33%) 
Index diagnosis readmission 2 5 
Readmission unrelated to initial diagnosis 1 3 
 
CHF=Congestive Heart Failure, PNA=Pneumonia, MI=Myocardial Infarction 
 
 
 
 
Table 3: Shows the frequency of drug related problems in the intervention group. 
Number of Drug Therapy Problems Detected Number of Patients 
0 2 
1-3 14 
3-6 2 
>6 0 
 
 
 
 
Table 4: Examples of medication discrepancies detected 
Problem Evaluation 
Communication/Documentation Failure (An example of 
an issue detected outside the normal scope of drug 
therapy problems due to system failure 
The patient’s discharge medication records indicated rosuvastatin, but 
the follow-up call found the patient was taking lovastatin.  This system 
level issue of conflicting information between sources is easily clarified 
for the primary care provider on the CMR documents. 
Adverse Drug Reaction A patient was discharged with an antibiotic and steroids for 
pneumonia.  During the follow-up call she described symptoms similar 
to thrush.  The pharmacist referred the patient to her physician for 
evaluation and treatment.  This is a patient level event. 
Dose too high  A patient was taking 80 mg of citalopram daily.  The maximum 
recommended dose is 40 mg daily. 
Needs Additional Drug Therapy Patients with a diagnosis of CHF were missing key drug therapies such as 
ACE-Inhibition or Beta Blockade. 
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Appendix A: 
Impact of Complete Medication Review (CMR) telephone discharge follow-up 
 to Reduce Readmissions and Drug Related Problems 
 
Name/Study Number 
 
Discharge Date: 
 
Date of Follow-Up Call 
 
Prepared to discuss all 
medications? 
Yes                       No 
What pharmacy do you use 
to fill your medications? 
(verify compliance) 
 
Did you have trouble getting 
your prescriptions filled 
after discharge? 
Yes                       No 
 
 
Patient Disease States: (circle all that apply)—PNA 
Astham/COPD Depression Heart Failure Mental Health OA/RA 
Cardiovascular Diabetes Hyperlipidemia Fluid Retention Osteoporosis 
GERD/PUD Hypertension Migraine Headaches Thyroid Disorders 
Seizures Chronic Pain Stroke Other-neuropathy 
 
Readmission Category: (circle all that apply) 
Post MI Pneumonia Heart Failure >5 medications 
 
Disease State Specific Questions: 
Current 
Medications 
Indication 
 
 
Dosing Duration Comments 
 
Asthma/COPD: 
Question Yes No Contrain
dicated 
Not 
Relev
ant 
Are you using a short-acting β2-agonist (SABA)/"rescue inhaler" more than 2 days 
a week (not including pre-exercise dose)? 
    
Based onreview and standards of care, is the patient’s medication therapy for 
asthma appropriate? 
    
Do you  understand the purpose of each medication used to treat asthma (rescue 
vs. controller, scheduled vs. as needed dosing) 
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Heart Failure: 
Question Yes No Contrain
dicated 
Not 
Relev
ant 
Is the patient currently taking a beta blocker?     
Is the patient currently taking a diuretic?     
Based on review and standards of care, is current medication therapy for Heart 
Failure appropriate? 
    
Are you weighing yourself daily?     
Does patient know to call his/her physician when weight gain of 2 lbs. or greater 
occurs overnight or 5 lbs. or greater occurs in one week? 
    
Are you experiencing symptoms of possible worsening of heart failure (weight 
gain, fluid retention, dry cough, increased shortness of breath, elevating the head 
with pillow(s) to sleep or sleeping sitting up)? 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
